Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
04:05pm, Tuesday, 19'th Nov 2024
Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
01:24pm, Monday, 18'th Nov 2024
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process f
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
11:47am, Sunday, 17'th Nov 2024
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 mi
6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale
08:44am, Sunday, 17'th Nov 2024
Key Points Yields have drifted higher since the Federal Reserve cut rates in September.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
06:49pm, Thursday, 14'th Nov 2024
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge ab
2 Beaten-Down Dividend Stocks to Buy and Hold
08:00am, Thursday, 14'th Nov 2024
They're down, but they aren't out, at least not in the eyes of patient investors.
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
07:41pm, Tuesday, 12'th Nov 2024
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
12:48pm, Tuesday, 12'th Nov 2024
Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
AbbVie's loss is Bristol Myers Squibb's gain - analyst
11:36am, Tuesday, 12'th Nov 2024
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
08:53am, Tuesday, 12'th Nov 2024
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
Buy, Sell, Or Hold BMY Stock?
07:22am, Tuesday, 12'th Nov 2024
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizo
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
04:08pm, Monday, 11'th Nov 2024
Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer,
